In vitro susceptibility of Sporothrix schenckii to six antifungal agents determined using three different methods

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 7, 2007, Pages 2420-2423

  Alvarado Ramírez, Eidi ^a   Torres Rodríguez, Josep M ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b INST MUNIC D INVESTIGACIO MEDICA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; VORICONAZOLE;

ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS FLAVUS; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CONTROLLED STUDY; DEVICE; FUNGAL STRAIN; IN VITRO STUDY; INTERMETHOD COMPARISON; MINIMUM INHIBITORY CONCENTRATION; MYCELIUM; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL; SPOROTHRIX SCHENCKII;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; FLUCONAZOLE; FLUCYTOSINE; HUMANS; ITRACONAZOLE; KETOCONAZOLE; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; QUALITY CONTROL; SPOROTHRIX; SPOROTRICHOSIS; TRIAZOLES;

EID: 34447291806     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01176-06     Document Type: Article

References (24)

1. Baker, J. H., H. C. Goodpasture, H. R. Kuhns, and M. G. Rinaldi. 1989. Fungemia caused by an amphotericin B-resistant isolate of Sporotrhix schenckii. Successful treatment with itraconazole. Arch. Pathol. Lab. Med. 113:1279-1281.
2. Brandsberg, J. W., and M. E. French. 1972. In vitro susceptibility of isolates of Aspergillus fumigatus and Sporothrix schenckii to amphotericin B. Antimicrob. Agents Chemother. 2:402-404.
3. Calhoun, D. L., H. Waskin, M. P. White, J. R. Bonner, J. H. Mulholland, L. W. Rumans, D. A. Stevens, and J. N. Galgiani. 1991. Treatment of systemic sporotrichosis with ketoconazole. Rev. Infect. Dis. 13:47-51.
4. Casali, A. K., and J. S. Hamdan. 1997. Effects of three azole derivatives on the lipids of different strains of Sporothrix schenckii. Can. J. Microbiol. 43:1197-1202.
5. Castrejón, O. V., M. Robles, and O. E. Zubieta. 1995. Fatal fungemia due to Sporothrix schenckii. Mycoses 38:373-376.
6. Ellis, D. 2002. Amphotericin B, spectrum and resistance. J. Antimicrob. Chemother. 49:7-10.
7. Espinel-Ingroff, A., K. Boyle, and D. J. Sheehan. 2001. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia 150:101-115.
8. Espinel-Ingroff, A. 1998. In vitro activity of the new triazole voriconazole (UK-109,996) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J. Clin. Microbiol. 36:198-202.
9. Espinel-Ingroff, A., K. Dawson, M. Pfaller, E. Anaissie, B. Breslin, D. Dixon, A. Fothergill, V. Paetznick, J. Peter, and M. Rinaldi. 1995. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antiomicrob. Agents Chemother. 39:314-319.
10. Kaufman, C. A., R. Hajjeh, S. W. Chapman, et al. 2000. Practice guidelines for the management of patients with sporotrichosis. Clin. Infect. Dis. 30: 684-687.
11. Kauffman, C. A. 1995. Old and new therapies for sporotrichosis. Clin. Infect. Dis. 21:981-985.
12. Kurosawa, A., S. C. Pollock, M. P. Collins, C. R. Kraff, and M. O. Tso. 1988. Sporotrhix schenckii endophtalmitis in a patient with human immunodeficiency virus infection. Arch. Optalmol. 106:376-380.
13. Martin-Mazuelos, E., J. Peman, A. Valverde, M. Chaves, M. C. Serrano, and E. Canton. 2003. Comparison of the Sensititre YeastOne colorimetric antifungal panel and Etest with the NCCLS M38-A method to determine the activity of amphotericin B and itraconazole against clinical isolates of Aspergillus spp. J. Antimicrob. Chemother. 52:365-370.
14. McGinnis, M. R., N. Nordoff, R. K. Li, L. Pasarell, and D. W. Warnock. 2001. Sporothrix schenckii sensitivity to voriconazole, itraconazole and amphotericin B. Med. Mycol. 39:369-371.
15. Morera-Lopez, Y., J. M. Torres-Rodriguez, and T. Jiménez- Cabello. 2005. Estudio de la sensibilidad in vitro de aislamientos clínicos de mohos y levaduras a itraconazol y voriconazol. Rev. Iberoam. Micol. 22:103-107.
16. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing for yeasts. Approved guideline M27-A2. National Committee for Clinical Laboratory Standards, Wayne, PA.
17. National Committee for Clinical Laboratory Standards. 2002. Reference methods for broth dilution antifungal susceptibility testing of filamentous fungi. Approved guideline M38-A. National Committee for Clinical Laboratory Standards, Wayne, PA.
18. Odabasi, Z., V. L. Paetznick, J. R. Rodríguez, E. Chen, and L. Ostrosky-Zeichner. 2004. In vitro activity of anidulafungin against selected clinically important mold isolates. Antimicrob. Agents Chemother. 48:1912-1915.
19. Pujol, I., J. Capilla, B. Fernandez-Torres, M. Ortopeda, and J. Guarro. 2002. Use of Sensititre colorimetric microdilution panel for antifungal susceptibility testing of dermatophytes. J. Clin. Microbiol. 40:2618-2621.
20. Schell, W. A. 1998. Agents of chromoblastomycosis and sporotrichosis, p. 323-336. In L. Ajello and R. J. Hay (ed.), Topley & Wilson's Medical Mycology, 9th ed. Arnold Press, London, United Kingdom.
21. Skrodeniene, E., A. Dambrauskiene, and A. Vitkausikene. 2006. Susceptibility of yeast to antifungal agents in Kaunas University of Medicine Hospital. Medicina (Kaunas) 42:294-299.
22. Ware, A. J., C. J. Cockerell, D. J. Skiest, and H. M. Kussman. 2000. Disseminated sporotrichosis with extensive cutaneous involvement in a patient with AIDS. J. Am. Acad. Dermatol. 40:350-355.
23. Weeke, J. 2000. Thyroid and antithyroid drugs, p. 1492-1493. In M. N. G. Dukes and J. K. Aronson (ed.), Meyler's side effects of drugs, 14th ed. Elsevier Press, Amsterdam, The Netherlands.
24. Winn, R. E., J. Anderson, J. Piper, N. E. Aronson, and J. Pluss. 1993. Systemic sporotrichosis treated with itraconazole. Clin. Infect. Dis. 17:210-217.